Fulcrum Therapeutics, Inc. (FULC)
Nasdaq · Healthcare · Biotechnology
$3.71+0.54%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $283M
- 52-week range
- $2.83 – $15.74
- 52-week change
- −61.16%
- EPS (trailing)
- −$1.21
- Next earnings
- Oct 29, 2026
Fiscal year to Dec 2025
- Revenue
- $0K (−100.00%)
- Net income
- −$74.9M
- Diluted EPS
- −$1.18
- Free cash flow
- −$60.4M
From the company’s annual report on SEC EDGAR.
About Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders. It has licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Headquarters: Cambridge, United States · 9 employees · fulcrumtx.com